Tr1X has won an FDA green light for a clinical trial testing TRX319, a cell therapy designed to restore immune balance, for ...

Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...

A 24-parameter spectral flow cytometry panel was developed to monitor immune receptor expression in MS patients, aiding personalized treatment approaches. The panel detects 12 treatment-associated ...

TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling and pathogenic T-cell modulation in a CNS-penetrant package $50 ...

The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. Current approved CAR T-cell therapy treatments rely ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

These blood vessels functioned like dedicated gateways, enabling large numbers of T and B cells to enter the tumors and assemble into TLSs. Within these TLS, B cells initiated germinal‑center ...

Rheumatoid arthritis (RA) is an autoimmune disease that affects millions worldwide and can have a devastating impact on patients' lives. Yet, about one in three patients respond poorly to existing ...